Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 30

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 30
---
 or decrease in the assumed public offering price would decrease or increase the accretion per share to new investors by $0.12, assuming that the number of shares of Common Stock and accompanying Common Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 100,000 shares of Common Stock offered by us would decrease the pro forma as adjusted net tangible book value after this offering by $0.01 per share and decrease the accretion per share to new investors by $0.01, and a decrease of 100,000 shares of Common Stock offered by us would increase the pro forma as adjusted net tangible book value by $0.01 per share and increase the accretion per share to new investors by $0.01, assuming that the assumed public offering price remains the same, and after deducting estimated Placement Agents’ fees and estimated offering expenses payable by us.

The table and discussion above are based on 15,122,873 shares of Common Stock outstanding as of December 31, 2024, and excludes the following:

• 141,996 Shares of Common Stock issued after December 31, 2024;

<div align='center'>17</div>

• 2,587,129 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $6.14 per share;

• 2,041,563 shares of Common Stock issuable upon the exercise of outstanding warrants to purchase Common Stock with a weighted average exercise price of $4.32 per share; and

• 1,881,649 additional shares of the Common Stock reserved for future issuance under our equity incentive plans, plus 529,300 additional shares of the Common Stock reserved for future issuance under our equity incentive plans authorized on January 1, 2025.

Unless otherwise indicated, the discussion and table above assume no exercise of the outstanding options and warrants described above after December 31, 2024 and excludes the shares of Common Stock to be issued upon exercise of the Common Warrants and Pre-Funded Warrants offered in this offering.

To the extent that any outstanding warrants or options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional shares in the future, there will be further dilution to new investors participating in this offering. In addition, we may choose to raise additional capital